May 20, 2024 10:55 AM EDT

AstraZeneca, Amgen tout Phase 2a Tezspire data in COPD ahead of Dupixent decision

Max Gelman

Senior Editor

AstraZeneca and Amgen laid out the full Phase 2a dataset for Tezspire in COPD at the American Thoracic Society’s International Conference on Sunday, providing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Amgen tout Phase 2a Tezspire data in COPD ahead of Dupixent decision

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

As­traZeneca, Am­gen tout Phase 2a Tezspire da­ta in COPD ahead of Dupix­ent de­ci­sion

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca, Amgen tout Phase 2a Tezspire data in COPD ahead of Dupixent decision